Navajas Hernández, P., Mouhtar El Halabi, S., González Parra, A. C., Valdés Delgado, T., Maldonado Pérez, B., Castro Laria, L., & Argüelles Arias, F. (2024). Carriage of the HLA-DQA1*05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease.

Navajas Hernández, Pilar, Samer Mouhtar El Halabi, Ana Caridad González Parra, Teresa Valdés Delgado, Belén Maldonado Pérez, Luisa Castro Laria, y Federico Argüelles Arias. Carriage of the HLA-DQA1*05 Haplotype Is Associated With a Higher Risk of Infratherapeutic Drug Concentration and Higher Immunogenicity in Patients Undergoing Treatment With Anti-TNF for Inflammatory Bowel Disease. 2024.

Navajas Hernández, Pilar, et al. Carriage of the HLA-DQA1*05 Haplotype Is Associated With a Higher Risk of Infratherapeutic Drug Concentration and Higher Immunogenicity in Patients Undergoing Treatment With Anti-TNF for Inflammatory Bowel Disease. 2024.